Related Experiment Video
Updated: Jul 17, 2026

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9
Published on: August 28, 2018
Molecular biology of PCSK9: its role in LDL metabolism
Jay D Horton1, Jonathan C Cohen, Helen H Hobbs
1Departments of Internal Medicine and Molecular Genetics, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9046, USA. Jay.Horton@utsouthwestern.edu
Abstract:
Proprotein convertase subtilisin-like kexin type 9 (PCSK9) is a newly discovered serine protease that destroys low density lipoprotein (LDL) receptors in liver and thereby controls the level of LDL in plasma. Mutations that increase PCSK9 activity cause hypercholesterolemia and coronary heart disease (CHD); mutations that inactivate PCSK9 have the opposite effect, lowering LDL levels and reducing CHD. Although the mechanism of PCSK9 action is not yet clear, the protease provides a new therapeutic target to lower plasma levels of LDL and prevent CHD.
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
Cholesterol: Significance and Regulation
Considering cholesterol and...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Receptor-mediated Endocytosis
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
Coronary Artery Disease IV: Preventive Measures
